Prevalence, risk factors, and treatment outcomes of isoniazid- and rifampicin-mono-resistant pulmonary tuberculosis in Lima, Peru [PDF]
, 2016 Background : Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis (TB) treatment. We assessed the prevalence of isoniazid and rifampicin mono-resistance, associated risk factors, and the association of mono-resistance ...
Gotuzzo, Eduardo +6 more
core +24 more sources
Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis. [PDF]
, 2016 BackgroundTuberculosis (TB) is the leading cause of death from an infectious pathogen worldwide and the most prevalent opportunistic infection in people living with HIV.
Bacchetti, Peter +6 more
core +1 more source
PLA Microparticles for Pulmonary Delivery of AntiTB drugs: Biodistribution study [PDF]
, 2008 A dry powder inhalable (DPI) microparticles comprising anti-tuberculosis drugs incorporated in biodegradable polymers was developed for the treatment of pulmonary tuberculosis (P. Muttil _et al_. 2007).
Amit Misra +4 more
core +2 more sources
Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. [PDF]
PLoS ONE, 2012 Multidrug resistant (MDR) tuberculosis is caused by Mycobacterium tuberculosis resistant to isoniazid and rifampicin, the two most effective drugs used in tuberculosis therapy.
Diana Machado +8 more
doaj +1 more source
Isoniazid causes heart looping disorder in zebrafish embryos by the induction of oxidative stress
BMC Pharmacology and Toxicology, 2020 Background The cardiotoxicity of isoniazid on zebrafish embryos and its underlying mechanism is unclear. Methods Here, we exposed zebrafish embryos at 4 h post-fertilization to different levels of isoniazid and recorded the morphology and number of ...
Jie Ni +10 more
doaj +1 more source
Molecules, 2022 Isoniazid and its metabolites are potentially associated with hepatotoxicity and treatment outcomes in patients who receive antituberculosis (TB) therapy.
Nguyen Ky Anh +6 more
doaj +1 more source
A Radioimmunoassay for Isoniazid
Clinical Chemistry, 1975 Abstract A sensitive radioimmunoassay is described, for measuring isoniazid in therapeutic and subtherapeutic concentrations. This radioimmunoassay was used in an exploratory clinical study to measure, as a function of time, the concentration of this drug in plasma of patients receiving isoniazid therapy.
Kam S. Tse +3 more
openaire +3 more sources
The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis [PDF]
, 2003 Patients in whom acid-fast bacilli smear-positive pulmonary tuberculosis was newly diagnosed were randomized to receive 400 mg moxifloxacin, 300 mg isonaizid, or 600 mg rifampin daily for 5 days. Sixteen-hour overnight sputa collections were made for the
Bongard, E +7 more
core +1 more source
Effects of low incubation temperatures on the bactericidal activity of anti-tuberculosis drugs [PDF]
, 2011 OBJECTIVES: to explore the effect of low incubation temperatures and the consequent slowing of bacterial metabolism on the bactericidal action of anti-tuberculosis drugs against Mycobacterium tuberculosis.
Coleman, David +2 more
core +2 more sources
Poor Compliance Makes Treatment of Latent Tuberculosis Infection Unsatisfactory
Journal of Primary Care & Community Health, 2012 Objectives: The recommended treatment for latent tuberculosis infection is isoniazid for 9 months, but this regimen has a low completion rate. The authors wanted to compare treatment with isoniazid and treatment with isoniazid and rifampin in the typical
Panupong Larppanichpoonphol +3 more
doaj +1 more source